DOCSLIB.ORG

P.6.C. 003. the BDNF Mimetic, GSB-106, Produсes Long

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
P.6.C. 003. the BDNF Mimetic, GSB-106, Produсes Long P.6.c. 003. The BDNF mimetic, GSB-106, produсes long-term analgesia and significant reduction of opiate withdrawal signs: comparison with dipeptide anxiolytic GB-115 effects in rats M.A. Konstantinopolsky ¹, T.A. Gudasheva ², L.G. Kolik ¹ V.V. Zakusov Institute of Pharmacology, ¹ Laboratory of Pharmacological Regulation of Addiction, ² Department of Medicinal Chemistry, Moscow, Russia [email protected] Introduction and Aim:. Antidepressants and Anxiolytics are used in clinical practice to eliminate the various features of opiate dependence. Some of them, benzodiazepine anxiolytics, especially, are able to produce the negative side effects [1]. New promising peptide origin medicines are safe and devoid of most disadvantages. Previously was shown, that cholecystokinin-4 (CCK-4) retro-analogue GB-115 (Ph|CH2|5-CO-Gly-L-Trp-NH2) exert anxiolytic-like activity and is capable to reduce the morphine withdrawal syndrome (WS) signs in rats [2,3], while the BDNF dipeptide mimetic GSB-106 [(bis-N-monosuccinil-seryl- lysine) hexamethylenediamide] exhibit antidepressant-like effect [4]. The present study has been initiated to investigate the potential antidepressant GSB-106 effects in comparison with those of anxiolytic GB-115 upon opiate WS, the pain thresholds and tolerance to morphine-induced analgesia in rats. The Methods. Incremental doses of morphine were injected i.p. to outbred male rats for 5 days followed by Naloxone (Du Pont De Nemours), 1mg/kg, to provoke acute WS. The peptides (GSB-106, 0.1-1.0 mg/kg; GB-115, 0.1-0.4 mg/kg;) have been injected i.p. 30 min before the test in the “open field” or daily 30 min before the morphine injections; after that the Total Index (TI) of WS was evaluated [5]. The pain thresholds in the water immersive «tail flick» test, in the «tail flick» and «hot plate» via “Ugo Basile apparatus”, the tolerance to morphine-induced analgesia were studied. Naltrexone (Sigma), 1mg/kg, i.p. was used to analyze the GSB-106 induced analgesia. Plantar tactile thresholds were measured in “von Frey” test. The acquisition of CPP after 5 days of morphine and GB- 115 injections on days 7 - 21-st were studied. For statistical assay Mann-Whitney-test, one way ANOVA and t-test were used. Catalepsy Tail flick & Hot plate Tests Rhinorrhea and nasal bleeding Flattening pose, ptosis, tonic seizures and writhing Morphine acute effects Signs of morphine withdrawal syndrome Dipeptide mimetic of THE BDNF CONFORMATION BDNF GSB-106 GB-115 Ph(CH2)5CO-Gly-Trp-NH2 OH H N NH2 HN O O O HN O OH O Von Frey test (tactile sensitivity test ) O HN O . H O O HN N NH2 H The influence of anxiolytic peptide GB-115 on «DA-related conception of addiction with HO possible neuropeptides involvement tolerance to morphine 180 Neuropeptides modulating effect StimulantsStimulants Effect of GSB-106 peptide on pain thresholds * * 160 + in tail flick test * VTA PFC *** 140 GABA -- DA * * n.accumbenc + Glut 160 *** * * * + 140 120 * * amygdala 120 Opiates Stimulants hippocampus 100 nicotine opiates 100 cannabis alcohol 80 80 60 modified from N. Latt et al. Addiction medicine, 2009 Dose (mg/kg) 60 40 Control (0,0) 40 20 GSB 106 (0,1) SUMMARY OF RESULTS level) the of base ( % threshold Pain 0 GSB-106 (1,0) 20 0,5 1 24 48 72 GB-115 in single doses eliminated individual features and decreased Time after injection, hours 0 TI of morphine WS by 38-46%, p < 0.05. Chronic administration of base of level) the ( % threshold Pain 30 min 45 min 30 min 45 min Effect of peptide GSB-106 upon the pain thresholds in 1-st day of experiment 5-th day of experiment morphine with GB-115 decreased the TI of WS by 29.8 – 35.7%, p < hot plate test Control GB-115 (o.1 ) morphine (2.0 ) GB-115 (0.1) + morphine ( 2.0 ) 0.05. GB-115 significantly increased analgesic action of morphine (up to *** *** *** 140 * - p < 0,05 ( Doses mg/kg ) ** * - p < 0,05 100 %, p < 0.01) and attenuated the tolerance to morphine by 23.8 %, p ** - p < 0,01 120 ** *** - p < 0,001 < 0.05. GSB-106 was more effective than GB-115, reducing the TI of WS 100 of the base level base ofthe Dose (mg/kg) % 80 Effect of GB-115 and GB-115+morphine by 55.2 - 45.6% (p < 0.001, p < 0.01) by single or chronic administration control (0,0) 60 combination on pain threshold in ‘tail flick test’ (0,1 mg/kg), correspondingly, in relation to “morphine+Naloxone” group. 40 GSB-106 (0,1) 450 GSB-106 significantly enhanced the pain thresholds in “tail flick” by * * 20 50,3% (p < 0.001) and in “hot plate” test by 28.8% (p < 0.01) at 24 h threshold, Pain GSB-106 (1,0) 400 * 0 Dose mg/kg point by low dose of 0.1 mg/kg. The peptide effect in “hot plate” test 0,5 1 24 48 72 350 1. control Time after injection, hours lasted 48 h at dose of 1.0 mg/kg. Antagonist of μ-opioid receptors 300 * 2. morphine (2.0) of the base of base level) the * * 3. GB-115 (0.1)+ GSB-106 and Naltrexone effect upon the pain % Naltrexone inhibited the peptide effect at 24 h point. The tactile ( 250 * morphine (2.0 ) thresholds in "tail flick" test 2 thresholds not changed significantly after GSB-106 was given to 160 4. GB-115 (0.1) *** 200 morphine-dependent rats: the thresholds recovered to the 34.5% level 140 Dose (mg/kg) 3 5. GB -115 (0.4) 120 ** *** ** ** * 150 6. GB -115 (1.0) control (0,0) 4 after single GSB-106 injection, comparing with “morphine + Naloxone” 100 1 of the base level base the of 100 % 80 5 p < 0,05 group level of 15.0 % (p = 0.08) and control as reference group (100 * - 60 GSB-106 ( 0,1) 50 6 %). 40 threshold Pain 0 20 GSB-106 (0,1)+ 15 30 45 60 90 120 min thresholds, Pain 0 NLTR (1,0) CONCLUSION 0,5 1 24 48 Time after injection, hours The influence of GSB-106 peptide Effect of chronic administration of GB-115 on tactile thresholds in Anxiolytic-like peptide, GB-115, and antidepressant-like peptide GSB- upon opiate WS in rats The influence of GSB-106 peptide on morphine-dependent rats 106, significantly decreased the morphine WS individual features and 2 behavioral signs of morphine WS 1,8 100 10 TI of WS. GB-106 effect was more profound. GB-115 significantly 1,6 90 * morphine chr+Nal ) 9 * 1,4 80 enhanced morphine analgesic action and attenuated the tolerance to 8 initial 1,2 70 scores ( value 7 morphine-induced analgesia. GB-106 had powerful, long-term vehicle+Nal 1 60 6 final analgesic effect at low systemic dose. GB-115, evidently, realizes its ## ** 0,8 50 5 ### ** 0,6 ### value ### ### 40 4 (grams) force Pressure *** *** actions by means of central CCK-receptors. Effects of GSB-106 maybe GSB- 0,4 *** *** 30 3 0,2 ***-Р < 0,001 106(once)+morph %) ( WS of Index Total a of Expression 20 mediated by interaction with BDNF (TrkB) - and opioid receptor 2 ### 0 ###-P < 0,001 chr+Nal 10 The Total Index ofWS Index Total The 1 1 2 3 4 systems of the brain. GSB-106 0 0 * chr+morph chr+Nal Experimental groups 1 2 3 4 Experimental groups References [1] Kelly T.M., Daley D.C., Douaihy A.B., 2012. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behaviour, Jan;37(1):11-24. [2] Konstantinopolsky M.A., Chernjakova I.V., Gudasheva T.A. New cholecyctokinin-4 retro-analogue and dipeptide analogue of neurotensine as opiate dependence correctors: an experimental study. Europ.Neuropsychoparmacology, 21, (2), s168, (2011) [3] Konstantinopolsky M.A., Kolik L.G., T.A. Gudasheva. New peptide-opigin anxiolytics, GB-115 and Selank, as possible tools in treatment of opiate addiction: an experimental study. Eur. Neuropsychopharmacology,, vol. 24, suppl.2, s676-s677, (2014) [4] Gudasheva T.A., Tarasiuk A.V., Pomogaibo S.V., Logvinov I.O., Povarnina P.Yu., Antipova T.A., Seredenin S.B., 2012. Design and synthesis of dipeptide mimetics of brain-derived neurotrophic factor. Bioorg. Khim., 38(3): 280-290 [5] Konstantinopolsky M.A., Cherniakova I.V. Afobazole decreases severity of morphine withdrawal syndrome: experimental evidence,. Eksp. Klin. Farmakology, 74(10):12-6, (2011) Disclosure statement : there is not potential conflict of interest . .
Load more

Recommended publications
  • Screening of 109 Neuropeptides on Asics Reveals No Direct Agonists
    www.nature.com/scientificreports OPEN Screening of 109 neuropeptides on ASICs reveals no direct agonists and dynorphin A, YFMRFamide and Received: 7 August 2018 Accepted: 14 November 2018 endomorphin-1 as modulators Published: xx xx xxxx Anna Vyvers, Axel Schmidt, Dominik Wiemuth & Stefan Gründer Acid-sensing ion channels (ASICs) belong to the DEG/ENaC gene family. While ASIC1a, ASIC1b and ASIC3 are activated by extracellular protons, ASIC4 and the closely related bile acid-sensitive ion channel (BASIC or ASIC5) are orphan receptors. Neuropeptides are important modulators of ASICs. Moreover, related DEG/ENaCs are directly activated by neuropeptides, rendering neuropeptides interesting ligands of ASICs. Here, we performed an unbiased screen of 109 short neuropeptides (<20 amino acids) on fve homomeric ASICs: ASIC1a, ASIC1b, ASIC3, ASIC4 and BASIC. This screen revealed no direct agonist of any ASIC but three modulators. First, dynorphin A as a modulator of ASIC1a, which increased currents of partially desensitized channels; second, YFMRFamide as a modulator of ASIC1b and ASIC3, which decreased currents of ASIC1b and slowed desensitization of ASIC1b and ASIC3; and, third, endomorphin-1 as a modulator of ASIC3, which also slowed desensitization. With the exception of YFMRFamide, which, however, is not a mammalian neuropeptide, we identifed no new modulator of ASICs. In summary, our screen confrmed some known peptide modulators of ASICs but identifed no new peptide ligands of ASICs, suggesting that most short peptides acting as ligands of ASICs are already known. Acid-sensing ion channels form a small family of proton-gated ion channels that belongs to the degenerin/epi- thelial Na+ channel (DEG/ENaC) gene family1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Efficacy of Peptide Anxiolytic Selank During Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation
    52 Bulletin of Experimental Biology and Medicine, Vol. 157, No. 1, May, 2014 PHARMACOLOGY AND TOXICOLOGY Effi cacy of Peptide Anxiolytic Selank during Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation L. G. Kolik, A. V. Nadorova, and M. M. Kozlovskaya Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 1567, No. 1, pp. 61-65, January, 2014 Original article submitted January 31, 2013 We studied the effects of selank on the development of symptoms of acute 48-h alcohol withdrawal in outbred rats drinking 10% ethanol as the only source of fl uid for 24 weeks. In alcohol-preferring animals (mean daily ethanol intake >5.0 g/kg) allowed free choice between 10% ethanol and water, single intraperitoneal injection of selank in a dose of 0.3 mg/kg eliminated anxiety induced by ethanol withdrawal in tests elevated plus maze and so- cial interaction tests and prevented the formation of mechanical allodynia without affecting ethanol consumption. The fi ndings suggest that selank is effective in eliminating of alcohol withdrawal symptoms in rats. Key Words: selank; alcohol withdrawal; anxiety; allodynia; rats Benzodiazepine anxiolytics temporary relieving man- by rapid onset of therapeutic effect and the absence of ifestation of psychopathological symptoms associ- undesirable side effects [4]. Experimental studies have ated with withdrawal syndrome play an important shown that it had a broad spectrum of psychotropic role in the complex medical therapy for alcoholism. activity and restored integrative activity of the CNS However, numerous side effects, such as respiratory impaired by neurotoxic factors of different genesis depression, excitement, potentiation of the narcogene [5].
    [Show full text]
  • Nootropics- Memory Boosters
    Harikumar K. et al. / Journal of Pharmaceutical Biology, 6(1), 2016, 14-19. Journal of Pharmaceutical Biology www.jpbjournal.com e-ISSN - 2249-7560 Print ISSN - 2249-7579 NOOTROPICS- MEMORY BOOSTERS K.Hari Kumar*, Mitta Srija, D.K.Sandeep, Ramisetty Davarika, Gunda Sai Mounica Department of Pharmacology, Sri Venkateswara College of Pharmacy, R.V.S.Nagar, Chittoor-517127, Andhra Pradesh, India. ABSTRACT Nootropics also called as smart drug, memory enhancers, neuron enhancers, cognitive enhancers and intelligent enhancers are drugs, supplements, neutraceuticals and functional foods that provide one or more aspects of mental function. Specific effect can include improvement to working memory motivation or attention. Nootropics drugs are able to promote, enhance and protect cognitive functions. As cognition is the typically human higher activity of brain, nootropic concept looked quite appealing for scores of people dreaming to enjoy better and longer lasting mental activity and for drug maker keen to produce such enviable products. There are large number of drugs which can be used as nootropic agents and help to enhance memory of people. Nootropics offer lot of benefits for cognitive aptitude and brain health. Nootropics used for the treatment of Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, dementia and cognitive symptoms of schizophrenia. Keywords: Nootropics, Huntington’s disease, Dementia, Alzheimer’s disease. INTRODUCTION It is derived from Greek words “NOOS –Mind” But non-ADHD medications and supplements are more “Tropein – Turn/Bend”. They are also called as memory frequently used for performance enhancement. Many enhancers, Smart nutrients, Cerebroactive drugs and individuals use these drugs for performance enhancement cognition enhancers.
    [Show full text]
  • 17Th European Society for Biomedical Research on Alcoholism Congress 21-24 September 2019, Lille – Invited Talks and Symposia Abstracts
    Directeur de la rédaction Pr François Paille Rédacteur en chef Pr Amine Benyamina Rédacteurs associés Dr Philippe Batel Dr Ivan Berlin Dr Laurent Karila Pr Michel Lejoyeux Pr Mickaël Naassila Rédactrice Sciences humaines Pr Myriam Tsikounas Rédactrice Sciences psychologiques Pr Isabelle Varescon-Pousson Comité de rédaction Pr Georges Brousse Pr Olivier Cottencin Dr Michel Craplet Pr Jean-Bernard Daeppen Dr Jean-Michel Delile Pr Maurice Dematteis Dr Claudine Gillet th Dr Geneviève Lafaye 17 European Society for Biomedical Research Pr Michel Reynaud Dr Alain Rigaud Dr Marc Valleur on Alcoholism Congress Directeur de la publication Pr Mickael Naassila 21-24 September 2019, Lille Comité scientifique Pr Jean Adès Pr Thomas F. Babor Pr Jean-Louis Balmès Pr Maurice Bazot Dr Mats Berglund Pr Jacques Besson Pr Jean-Pierre Blayac Pr Jonathan D. Chick Mme Marie Choquet Pr Philippe de Witte Pr Michel Escande Pr Claude Got Dr Antoni Gual Pr Momar Gueye Pr Roger Henrion Pr Denise Kandel Pr Michel Le Moal Pr Karl Mann Mme Véronique Nahoum-Grappe Dr José Maria Neves Cardoso Pr Philippe-Jean Parquet Pr Jean-Louis Pedinielli Pr Falvio Poldrugo Pr Bernard Roques Pr John A. Talbott Pr Jean-Luc Vénisse Pr Lars von Knorring Pr Jacques Weill Pr Jean-Jacques Yvorel ISSN 2554-4853 Trimestriel Société Française PRINCEPS Éditions SEPTEMBRE-DÉCEMBRE 2019 - Tome 41, n° 3-4 d’Alcoologie !BSTRACTS CONGRÈS Pr Mickael Naassila* * President 17th ESBRA Meeting 17th European Society for Biomedical Research on Alcoholism congress 21-24 September 2019, Lille – Invited talks and Symposia abstracts Invited talks forward, such as combining training with neurostimulation.
    [Show full text]
  • Furosemide in the Treatment of Generalized Anxiety Disorder: Case Report and Review of the Literature
    International Research Journal of Pharmacy and Pharmacology (ISSN 2251-0176) Vol. 3(5) pp. 67-76, May 2013 Available online http://www.interesjournals.org/IRJPP Copyright © 2013 International Research Journals Case Report Furosemide in the treatment of generalized anxiety disorder: Case report and review of the literature *1 Dr. S. E. Oriaifo, 2Prof. E. K. I. Omogbai, 3Dr. N. I. Oriaifo, 3Dr. M. O. Oriaifo and 4Dr. E. O. Okogbenin *1Department of Pharmacology and Therapeutics, AAU, Ekpoma 2Department of Pharmacology and Toxicology, University of Benin, Benin-City, Nigeria. 3DepartmentOf Obstetrics and Gynaecology, Irrua Specialist Teaching Hoispital, Irrua 4Department of Psychiatry, Irrua Specialist Teaching Hospital, Irrua and Department of Psychiatry, Ambrose Alli University, Ekpoma. Accepted May 15, 2013 Generalised anxiety disorder (GAD) is the most common of the anxiety disorders seen in primary care and the 12-month prevalence in Nigeria may exceed 2.8%. The aim of this case-report is to highlight the use of furosemide in generalised anxiety disorder comorbid with dizziness in an adult female patient. Low-dose furosemide, 20mg to 40mg daily, attenuated the symptoms of generalised anxiety disorder, diagnosed in a young female patient with the Penn State Worry Questionnaire. It ameliorated the symptoms of pessimistic worry, muscle tension, dizziness, easy fatiguability, poor concentration, insomnia and irritability when used alone. Furosemide’s action in GAD may be due to its down- regulation of protein kinase C signalling which may be critical in establishing and maintaining a hyperglutamatergic state in key brain areas. Furosemide’s action may thus significantly reduce the simplified excitotoxicity index of glutamate/gamma-amino butyric acid.
    [Show full text]
  • Selank and Semax As Potential Hepatoprotectors in Medical
    Research Results in Pharmacology 5(4): 33–39 UDC: 615.331 DOI 10.3897/rrpharmacology.5.38769 Research Article Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis Alexey K. Petrovsky1, Nikolay A. Smirnov1, Vladimir P. Vdovichenko2, Tatiana B. Fedorova1, Edgar E. Kerbenev1, Vladimir N. Fedorov1 1 Yaroslavl State Medical University, 5 Revolyutsionnaya St., Yaroslavl 150000, Russian Federation 2 Grodno State Medical University, 80 Gorky St., Grodno 230009, Republic of Belarus Corresponding author: Alexey K. Petrovsky ([email protected]) Academic editor: Mikhail Korokin ♦ Received 2 August 2019 ♦ Accepted 24 October 2019 ♦ Published 16 December 2019 Citation: Petrovsky AK, Smirnov NA, Vdovichenko VP, Fedorova TB, Kerbenev EE, Fedorov VN (2019) Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis. Research Results in Pharmacology 5(4): 33–39. https://doi. org/10.3897/rrpharmacology.5.38769 Abstract Introduction: Drug-induced hepatitis is common in clinical practice. This problem is particularly relevant in the treat- ment of tuberculous infection, because for this purpose, up to 5–6 hepatotoxic drugs are used simultaneously for a long time, which often (in 15–20% of cases) leads to medical liver lesion. To protect the liver, Semax and Selank are offered – drugs of regulatory peptides group. Materials and Methods: The research was conducted on 96 outbred white male rats weighing 180–220 g. The experi- mental group included about 10 animals. Drug-induced hepatitis was simulated through the combined 21-day adminis- tration of isoniazid, rifampicin and ethanol. Semax and Selank, as well as Essentiale N and Mexidol (comparison drugs) were administered once a day during the experiment.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0051350 A1 Zhu Et Al
    US 20170051350A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0051350 A1 Zhu et al. (43) Pub. Date: Feb. 23, 2017 (54) METHOD AND SYSTEM TO PREDICT (60) Provisional application No. 61/800,206, filed on Mar. RESPONSE TO TREATMENTS FOR 15, 2013, now abandoned, provisional application MENTAL DISORDERS No. 61/800,278, filed on Mar. 15, 2013, now aban doned. (71) Applicant: Pathway Genomics Corporation, San O Diego, CA (US) (72) Inventors: Guangdan Zhu, San Diego, CA (US); Publication Classification Cindy Wang, San Diego, CA (US); (51) Int. Cl Tanya Moreno, San Diego, CA (US); cio i/68 (2006.01) Andrew Hellman, San Diego, CA G06F 9/00 2006.01 (US); Alok Tomar, San Diego, CA ( .01) (US); Svetlana Ivanova Gramatikova, (52) U.S. Cl. San Diego, CA (US); Aditi Chawla, CPC ......... CI2O 1/6883 (2013.01); G06F 19/3431 San Diego, CA (US); Russell Kuo-fu (2013.01); G06F 19/704 (2013.01); C12O Del Tredici, San Diego, CA (US); (2013.01) Adrian Vilalta, San Diego, CA (US); K. David Becker, San Diego, CA (US); Michael Nova, San Diego, CA (US) (57) ABSTRACT (21) Appl. No.: 15/143,263 (22) Filed: Apr. 29, 2016 The present inventions relates to methods and assays to O O predict the response of an individual to a psychiatric treat Relatedelated U.S. Application DatUata ment and to a method to improve medical treatment of a (63) Continuation of application No. 13/917,573, filed on disorder, which is responsive to treatment with a psychiatric Jun. 13, 2013, now abandoned.
    [Show full text]
  • Tailor Made Compounding
    PEPTIDE CATALOG TAILOR MADE COMPOUNDING Phone: 1 859 887 0013 | Email: [email protected] Our Story | 04-05 MK-677 | 36 Peptide Fact Sheets | 06-55 Myristyl | 37 3-Desoxy DHEA | 08 NMN | 38 5-Amino-1MQ | 09 PEG-MGF | 39 Amlexanox | 10 Pentosan Polysulfate | 40 AMT | 11 PNC-27 | 41 Aniracetam | 12 PT-141 | 42 AOD 9604 | 13 PTD-DBM | 43 AOD 9604 + HA | 14 RG3, Methylcobalamin, NAD+ | 44 BPC-157 | 15 Sarms LGD-4033 | 45 Cerebrolysin | 16 Selank | 46 CJC-1295 | 17 Semax | 47 DHH-B | 18 Tesamorelin | 48 Dihexa | 19 Tesofensine | 49 DSIP | 20 Tetradecylthioacetic Acid (TTA) | 50 Eclomiphene | 21 Thymosin Alpha-1 | 51 Epitalon | 22 Thymosin Beta | 52 FGL (l) | 23 VIP | 53 GHK-Cu | 24 Zinc Thymulin | 54 TABLE OF TABLE Glycyrrhetinic Acid & Aminophylline Dosing Charts | 25 56-62 Transdermal Fat Loss Cream Licensed States | 64-65 IGF-1 | 26 TMC App | 66-67 Ipamorelin | 27 Contact Us | 68 iRGD | 28 Kisspeptin-10 | 29 KPV | 30 Leuphasyl | 31 LL-37 | 32 Malanotan II | 33 Met-Enkephalin | 34 MOTS-c | 35 CONTENTS Tailor Made Compounding was launched United States. Since the inception of TMC, in the U.S. in January of 2016. We have we have sourced and compounded over 40 since become a major contributor to unique peptides. We are proud to be the peptide medicines in the integrative first in the United States to offer health space. compounds like CJC 1295, Bremelanotide, OUR PT 141, BPC-157, and Epitalon and Through our compounding expertise, continue to introduce new and exciting knowledge and experience, we have compounds to our formulary.
    [Show full text]
  • P.6.C.014. ACTH4-10 Analogue Semax and Adamantane Derivative Hemantane Produce Significant Reduction of Withdrawal Signs in Morphine-Dependent Rats M.A
    P.6.c.014. ACTH4-10 analogue Semax and Adamantane derivative Hemantane produce significant reduction of withdrawal signs in morphine-dependent rats M.A. Konstantinopolsky ¹, L.G. Kolik ¹ V.V. Zakusov Institute of Pharmacology, ¹ Laboratory of Pharmacological Regulation of Addiction, Moscow, Russia, [email protected] Introduction :. The mechanism of opioid-like addiction has defined connections with DA-ergic reward system as well as with glutamate and NMDA systems of the brain. At the same time, some neuropeptides, namely, CCK analogues and one of taftsin derivatives, are able to reduce the severity of withdrawal signs in morphine-dependent rats [1,2] that give as the opportunity to suggest the modulating effect of these peptides in relation to opioid induced addiction. These facts have been considered when searching for new compounds with different action mechanisms to prevent and relieve the state of dependence. The main effects of Semax are its nootropic, neuroprotective and anxiolytic activity with the participation of serotonergic and CCK-receptors and, possible, BDNF [3], while Hemantane and Adamantane have an well-marked antiparkinsonian activity with the involvement of glutamatergic and NMDA receptor mechanisms [4]. Aim The present study was started to investigate the effects of the adrenocorticotropic hormone fragment, ACTH4-10, geptapeptide Semax (Inst. of Mol. Genetics RAN, Moscow) in comparison with those of Hemantane (N-adamant-2-yl-hexamethyleneimine hydrochloride, V.V. Zakusov Inst. of Pharmacology, Moscow) and Amantadine hydrochloride (1-aminoadamantane hydrochloride, Sigma-Aldrich), as a reference drug, upon opiate withdrawal syndrome (WS), tactile thresholds in “von Frey test”(Ugo Basile) and ambulation in the “open field”(OF) Methods.
    [Show full text]
  • Leu-Enkephalin Generally Labeled with Tritium in Studying the Selank Inhibiting Effect on the Enkephalin-Degrading Enzymes of Human Blood Plasma Yu
    Russian Journal of Bioorganic Chemistry, Vol. 30, No. 3, 2004, pp. 207–212. Translated from Bioorganicheskaya Khimiya, Vol. 30, No. 3, 2004, pp. 234–240. Original Russian Text Copyright © 2004 by Zolotarev, Sokolov, Kost, Vaskovsky, Myasoedov, Zozulya. Leu-Enkephalin Generally Labeled with Tritium in Studying the Selank Inhibiting Effect on the Enkephalin-Degrading Enzymes of Human Blood Plasma Yu. A. Zolotarev*, 1 O. Yu. Sokolov**, N. V. Kost**, B. V. Vaskovsky***, N. F. Myasoedov*, and A. A. Zozulya** *Institute of Molecular Genetics, Russian Academy of Sciences, pl. akademika Kurchatova 46, Moscow, 123182 Russia **National Research Center for Mental Health, Russian Academy of Medical Sciences, Moscow, Russia ***Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, GSP Moscow, 117997 Russia Received February 13, 2003; in final form, May 27, 2003 Abstract—A method of analysis of enkephalinase activity in blood plasma based on the application of Leu- enkephalin generally labeled with tritium at all its amino acid residues was developed. The method allows the simultaneous estimation of activity of several peptidases in microquantities of tissues. [G-3ç]Leu-enkephalin was prepared by the method of solid phase catalytic isotope exchange (120 Ci/mmol) and subjected to proteol- ysis by the treatment with blood plasma. The resulting radioactive metabolites were separated by HPLC in the presence of the mixture of unlabeled fragments of Leu-enkephalin as internal standards. It was shown that ami- nopeptidases, dipeptidylaminopeptidases, and dipeptidylcarboxypeptidases respond for approximately 80%, 2%, and 10% of the total enzymatic activity, respectively. The new pathway of degradation of Leu-enkephalin by carboxypeptidase that provides for ~6% of the total enkephalin-degrading activity was discovered.
    [Show full text]
  • Brain Health with Cerebrolysin and Other Peptides Cerebrolysin
    Brain Health with Cerebrolysin and Other Peptides Cerebrolysin ● A combination of nerve growth factors which aid in the repair and recovery of nerve cells within the brain and PNS. ● Neuro-protective/Neuro-regenerative: neurotrophic repair properties similar to NGF (nerve growth factors, BDNF) ● Neuropeptide; synthetic nootropic ● LMW can cross BBB/B-CSF Cerebrolysin: Therapeutic Uses ● Concussion/CTE, TBI ● Alzheimer’s Dementia, MCI ● CVA, TIA ● Mood Dysregulation Cerebrolysin in Dementia ● Decreases Beta Amyloid deposition ● Decreases Tau protein phosphorylation ● Increases synaptic density Cerebrolysin in Dementia ● Restores neuronal cyto-architecture ● Results in improved cognitive and behavioral performance ● To consider if ApoE→ E3/E4 or E4/E4 Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Z.H. Wei, et al. ● An infusion with Cerebrolysin for 4 weeks (30 ml Cerebrolysin daily on five consecutive days of each week) led to a significant improvement of the clinical global impression. ● Compared with placebo, log(OR) was 1.1799, and 95% confident interval was 0.7463–1.6135 (P < 0.05), indicating that Cerebrolysin could significantly improve the clinical global impression in patients with mild to moderate AD. ● Cerebrolysin consists of 25% LMW peptides and free amino acids that easily penetrate the BBB and allow for rapid efficacy. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound Cerebrolysin™ E. Rockenstein, et al. ● Cerebrolysin has the ability of improving synaptic functioning and reducing amyloid deposition. ● Cbl decreased amyloid deposition; these effects accompanied by a reduction in perivascular microgliosis and astrogliosis and increased expression of markers of vascular fitness such as CD31 and ZO-1.
    [Show full text]